These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 35916053)

  • 1. Methadone use is associated with increased levels of sCD14, immune activation, and inflammation during suppressed HIV infection.
    Azzoni L; Giron LB; Vadrevu S; Zhao L; Lalley-Chareczko L; Hiserodt E; Fair M; Lynn K; Trooskin S; Mounzer K; Abdel-Mohsen M; Montaner LJ
    J Leukoc Biol; 2022 Oct; 112(4):733-744. PubMed ID: 35916053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen Presenting Cells Contribute to Persistent Immune Activation Despite Antiretroviral Therapy Initiation During Hyperacute HIV-1 Infection.
    Naidoo KK; Ndumnego OC; Ismail N; Dong KL; Ndung'u T
    Front Immunol; 2021; 12():738743. PubMed ID: 34630420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
    Andraka-Christou B; Atkins D
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 7. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individuals.
    Giron LB; Azzoni L; Yin X; Lynn KM; Ross BN; Fair M; Damra M; Sciorillo AC; Liu Q; Jacobson JM; Mounzer K; Kostman JR; Abdel-Mohsen M; Montaner LJ; Papasavvas E
    AIDS; 2020 Aug; 34(10):1461-1466. PubMed ID: 32675559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of illicit opioid use on markers of monocyte activation and systemic inflammation in people living with HIV.
    Kholodnaia A; So-Armah K; Cheng D; Gnatienko N; Patts G; Samet JH; Freiberg M; Lioznov D
    PLoS One; 2022; 17(5):e0265504. PubMed ID: 35511802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
    Hattab S; Guihot A; Guiguet M; Fourati S; Carcelain G; Caby F; Marcelin AG; Autran B; Costagliola D; Katlama C
    BMC Infect Dis; 2014 Mar; 14():122. PubMed ID: 24589015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Opioid Use on Immune Activation and HIV Persistence on ART.
    Azzoni L; Metzger D; Montaner LJ
    J Neuroimmune Pharmacol; 2020 Dec; 15(4):643-657. PubMed ID: 32974750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.
    Wallet MA; Rodriguez CA; Yin L; Saporta S; Chinratanapisit S; Hou W; Sleasman JW; Goodenow MM
    AIDS; 2010 Jun; 24(9):1281-90. PubMed ID: 20559035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms in the CD14 gene are associated with monocyte activation and carotid intima-media thickness in HIV-infected patients on antiretroviral therapy.
    Yong YK; Shankar EM; Westhorpe CLV; Maisa A; Spelman T; Kamarulzaman A; Crowe SM; Lewin SR
    Medicine (Baltimore); 2016 Aug; 95(31):e4477. PubMed ID: 27495090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 17. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
    Pasman E; Lee G; Kollin R; Rodriguez B; Agius E; Madden EF; Resko SM
    Subst Use Misuse; 2022; 57(12):1828-1836. PubMed ID: 36041008
    [No Abstract]   [Full Text] [Related]  

  • 19. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
    Madden EF; Prevedel S; Light T; Sulzer SH
    Subst Use Misuse; 2021; 56(14):2181-2201. PubMed ID: 34538213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
    Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
    Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.